anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Attention-deficit/hyperactivity disorder (ADHD) and chronic pain are prevalent and associated. We examined the prevalence and distribution of chronic pain in adolescents and young adults with ADHD using 9-years longitudinal data (from T1:2009-2011 to T3:2018-2019) with three time points from a clinical health survey compared to two age-matched reference population-based samples. Mixed-effect logistic regression and binary linear regression were used to estimate the probability for chronic and multisite pain at each time point and to compare the prevalence of chronic pain with the reference populations. The prevalence of chronic and multisite pain was high in those with ADHD, especially in female young adults, with highly prevalent chronic pain at 9 years of follow-up (75.9%) compared to 45.7% in females in the reference population. The probability of having pain was only statistically significant for chronic pain in males at 3 years of follow-up (41.9%, p = 0.021). Those with ADHD were at higher risk of reporting single-site and multisite pain compared to the general population at all measurement points. Longitudinal studies should be tailored to further understand the complex sex differences of comorbid chronic pain and ADHD in adolescents, exploring predictive factors of pain assessing long-term associations with bodyweight, psychiatric comorbidities, and possible mechanisms of stimulant use effects on pain.
Atelvia, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when Atelvia is given to patients with active upper gastrointestinal problems (such as known Barrett’s esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis or ulcers) [see Contraindications (4), Adverse Reactions (6.1), Information for Patients (17)]. 

Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates. In some cases, these have been severe and required hospitalization. Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue Atelvia and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. 

The risk of severe esophageal adverse experiences appears to be greater in patients who lie down after taking oral bisphosphonates and/or who fail to swallow it with the recommended 4 ounces of water, and/or who continue to take oral bisphosphonates after developing symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [see Dosage and Administration (2)]. In patients who cannot comply with dosing instructions due to mental disability, therapy with Atelvia should be used under appropriate supervision. 

There have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials.
The efficacy of gemcitabine was evaluated in two trials (Studies 5 and 6), a randomized, single-blind, two-arm, active-controlled trial (Study 5) conducted in patients with locally advanced or metastatic pancreatic cancer who had received no prior chemotherapy and in a single-arm, open-label, multicenter trial (Study 6) conducted in patients with locally advanced or metastatic pancreatic cancer previously treated with fluorouracil or a fluorouracil-containing regimen. In Study 5, patients were randomized to receive either gemcitabine 1,000 mg/m2 intravenously over 30 minutes once weekly for 7 weeks followed by a one-week rest, then once weekly for 3 consecutive weeks every 28-days in subsequent cycles (n=63) or fluorouracil 600 mg/m2 intravenously over 30 minutes once weekly (n=63). In Study 6, all patients received gemcitabine 1,000 mg/m2 intravenously over 30 minutes once weekly for 7 weeks followed by a one-week rest, then once weekly for 3 consecutive weeks every 28-days in subsequent cycles. 

The major efficacy outcome measure in both trials was "clinical benefit response". A patient was considered to have had a clinical benefit response if either of the following occurred: 

  * The patient achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card) or analgesic consumption, or a 20-point or greater improvement in performance status (Karnofsky Performance Status) for a period of at least 4 consecutive weeks, without showing any sustained worsening in any of the other parameters. Sustained worsening was defined as 4 consecutive weeks with either any increase in pain intensity or analgesic consumption or a 20-point decrease in performance status occurring during the first 12 weeks of therapy.  
OR 
  * The patient was stable on all of the aforementioned parameters and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation. 



Study 5 enrolled 126 patients. Demographics and baseline characteristics were similar between the arms (Table 22). The efficacy results are shown in Table 23 and Figure 4. Patients treated with gemcitabine had statistically significant increases in clinical benefit response, survival, and time to disease progression compared to those randomized to receive fluorouracil. No confirmed objective tumor responses were observed in either treatment arm. 

Figure 4: Kaplan-Meier Curves for Overall Survival in Study 5
They will all be implanted but not activated for the Initial Study Period (24 weeks), followed by all subjects assigned to treatment (Control Group with device activation) in the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA.
BACKGROUND: Premenstrual syndrome (PMS) is a prevalent health issue impacting women, significantly impacting their well-being and fostering a negative attitude of femininity and menstruation. We investigated the effect of group counseling based on positive psychology on the severity of PMS symptoms.
METHODS: Participants in the intervention group engaged in six online sessions of group counseling focused on positive psychology via WhatsApp. Data were collected using the Premenstrual Symptoms Screening Questionnaire (PSST) before, immediately, and two months post-intervention. Analytical assessments were performed using SPSS 16 software using Chi-square, independent t-tests, and repeated measures analysis of variance (ANOVA). Comparative analyses were carried out using the Bonferroni post hoc test with a 95% confidence level.
RESULTS: The mean intensity of PMS symptoms in the intervention group significantly decreased from 21.60 (2.50) to 13.35 (4.727) and 14.750 (5.963) immediately and two months after the intervention; however, the difference was not significant in the control group. The results of repeated measures ANOVA showed that the effect of the intervention over time and the interaction between time and group were significant. The Eta effect size was about 0.20 and 16%, respectively (p = 0.001). According to Bonferroni post hoc test results, the difference in the mean scores of the severity of PMS symptoms before the intervention was statistically significant compared to both follow-up periods (p ≤ 0.007). However, the difference in mean scores immediately after the intervention compared to two months after the intervention was not statistically significant (p = 0.42).
CONCLUSION: Using a positive counseling approach demonstrates efficacy in alleviating the severity of PMS symptoms in the short term. While all women can benefit from such interventions, targeting adolescents is particularly strategic, as early interventions can foster positive attitudes toward menstruation. Additionally, social media platforms like WhatsApp provide a feasible and engaging medium for adolescent health interventions. Integrating this approach into adolescent health promotion package appears to be a viable measure worthy of consideration by relevant policymakers.
TRIAL REGISTRATION: Current Controlled Trials IRCT20201113049377N1, Date of Registration 2020, 12, 08.
The invention provides hydrogel with both adhesiveness and lipophilicity, and a preparation method and application thereof, and belongs to the technical field of biological medicines. The hydrogel is prepared from a dioleoyl phosphatidyl glycerol solution, a polyvinyl alcohol solution and a sodium borate solution according to the volume ratio of 1: (1-5): and (1) to (5) and then heating and cooling the mixture. The hydrogel provided by the invention has good adhesiveness and lipophilicity, and meanwhile has good biocompatibility. The hydrogel is not only beneficial to local administration of oral cavity, but also can promote permeation of the carried lipophilic medicament after carrying the lipophilic medicament, improves the treatment effect of the medicament, and has excellent prevention and/or treatment effect when being used for oral cavity white spot canceration. After the rapamycin is carried on the hydrogel, the incidence rate of oral cavity white spot canceration is obviously reduced. The hydrogel has good application prospect for clinically treating oral cavity white spot canceration.
Estimated radiation absorbed doses per injected activity for organs and tissues of adult male patients following an intravenous bolus of Gallium Ga 68 Gozetotide Injection are shown in Table 2. 

The effective radiation dose resulting from the administration of 259 MBq (7 mCi) is about 4.4 mSv. The radiation doses for this administered dose to the critical organs, which are the kidneys, urinary bladder, and spleen, are 96.2 mGy, 25.4 mGy, and 16.8 mGy, respectively.

These radiation doses are for Gallium Ga 68 Gozetotide Injection alone. If CT or a transmission source are used for attenuation correction, the radiation dose will increase by an amount that varies by technique.

Table 2: Estimated Radiation Absorbed Dose per Injected Activity in Selected Organs and Tissues of Adults after Intravenous Administration of Gallium Ga 68 Gozetotide Injection
It consists of 23 pregnant women. They will take Anti-hypertensive drug (Methyldopa 250 mg according to physician instructions).
The invention relates to antithrombotic Chinese medicinal powder and a preparation method thereof, and belongs to the technical field of new medicaments. The antithrombotic Chinese medicinal powder consists of the following medicinal materials: a venin microcrystalline cellulose inclusion complex, leech polypeptide, Tuo tea CO2 extract powder, schisandra CO2 extract powder, fine ganoderma lucidum powder, fine red paeony root powder, fine kudzuvine root powder, fine thinleaf milkwort root-bark powder, fine membranous milkvetch root powder, fine dwarf lilyturf tuber powder, and fine grassleaf sweelflag rhizome powder; and the prepared medicinal material powder is uniformly mixed and packaged by weight for later use. The antithrombotic Chinese medicinal powder is orally taken 30 minutes before a meal, three times per day, and 1 g each time. The antithrombotic Chinese medicinal powder is disabled for hemorrhagic diseases, hematemesis, hemoptysis and people subjected to major internal organ operation within a month. The antithrombotic Chinese medicinal powder is developed on the basis of the basic treating principle for apoplexia in Chinese medical science, the main medicaments primarily play a role in promoting blood circulation and removing blood stasis, the adjuvants primarily play a role in promoting intelligence and tranquilizing the mind, and the adjunctive medicaments primarily play a role in tonifying Qi and regulating. The antithrombotic Chinese medicinal powder can effectively treat cerebral thrombosis, cerebral circulation insufficiency, miocardial infarction, angina, vasculitis, phlebothrombosis, hyperviscosity and the like.
BACKGROUND: Dyskinesia is one of the most common complications of stroke. Acupuncture therapy (AT) and mirror therapy (MT) are promising rehabilitation measures for the treatment of post-stroke dyskinesia. Although some studies suggested that AT and MT are effective and safe for dyskinesia, the effects, and safety remain uncertain due to lacking strong evidence. The purpose of this study is to investigate the efficacy and safety of AT combined with MT in the treatment of post-stroke dyskinesia.
METHODS: We searched the following databases: PubMed, Web of Science, Cochrane Library, EMBASE, Medline, China Knowledge Network, WANFANG, and China Biomedical Literature Database, from inception to 1 January 2023 to identify eligible studies. Total effective rate, the Fugl-Meyer assessment scale (FMA) upper and lower limb scores, modified Barthel index scores, Berg balance scale, modified Ashworth scale, and adverse reactions were adopted as outcome indicators. The Grading of Recommendations Assessment Development and Evaluation system was used by 2 independent reviewers to assess the quality of evidence for the outcome indicators included in the study. The statistical analysis was conducted by RevMan V.5.4 software.
RESULTS: A total of 24 randomized controlled studies included 2133 patients with post-stroke dyskinesia were included. The total effective rate of AT combined with MT was more advantageous in the treatment of post-stroke dyskinesia (relative risk = 1.31, 95% confidence interval [CI] [1.22-1.42], Z = 6.96, P < .0001). AT combined with MT was more advantageous for FMA upper limb score (mean difference [MD] = 6.67, 95% CI [5.21-8.13], Z = 8.97, P < .00001) and FMA lower limb score (MD = 3.72, 95% CI [2.81-4.63], Z = 7.98, P < .00001). Meta-analysis showed that AT combined with MT for post-stroke dyskinesia had a more advantageous modified Barthel index score (MD = 9.51, 95% CI [7.44-11.58], Z = 9.01, P < .00001).
CONCLUSION: AT combined with MT is effective in improving motor function and daily living ability of patients, especially in improving muscle spasms. However, these results should be regarded with caution given the low quality of evidence for the evaluation results.
Patients will be introduced to Maze Out. 15 weeks later they will follow the same procedure as intervention group.
Introduction: At the end of life, the prevalence of delirium and pain is high. Current therapy is not satisfactory. Dexmedetomidine could be useful in the control of delirium and pain but is not approved outside of intensive care setting. Our objectives are to evaluate existing evidence in the literature that assessed the efficacy of dexmedetomidine in pain and delirium control and its safety in palliative care patients outside intensive care units. This systematic review was prospectively registered with PROSPERO and included a risk of bias assessment. Methods: PubMed and SCOPUS were examined for literature published until 2023. Experimental, cohort, cross-sectional, case-control studies, and case series/reports were included if they evaluate the use of dexmedetomidine in delirium and/or pain management in hospitalized palliative care adult patients. Studies were excluded if they were carried out in intensive care units. Results: Of the initial 529 records, 14 were included. Although only two studies were randomized trials, most were small and only one had low risk of bias. In most case reports and in the two retrospective cohort studies, dexmedetomidine appears to be a better option for these symptoms, although differences were not significant in the randomized trials. Discussion: Dexmedetomidine seems to be a promising option for refractory pain and delirium and may contribute to a reduction in opioid administration to control pain. This is the first systematic review of dexmedetomidine in palliative care. Quality evidence is limited, but clinical properties of dexmedetomidine justify the conduction of controlled trials in palliative care.
Pancreatic cancer is the fourth leading cause of cancer death in the United States. Every year, about 30,000 new patients are diagnosed with pancreatic cancer, and most will die within the year. The few patients that live beyond one year are those who have operable tumors whose cancer has not spread beyond the pancreas. There is no effective treatment for pancreatic cancer that impacts survival beyond a few more months. Therefore, innovative treatments are urgently needed. A number of experimental therapies are currently under investigation, and gene therapy is a viable therapeutic option.

A gene called cyclin G1 has been shown to play a very important part in cancer growth. In animal experiments, when this cyclin G1 gene is blocked, the cancer cells grow much slower or even die. This study will test the drug, Rexin-G, which contains a gene that works by getting rid of the cyclin G1 gene. The new gene will get into the tumor cells using a "vehicle" to carry it into the cells. The "vehicle" that will be used is a virus that has been changed so that it is not likely to cause disease. This "vehicle" is called a vector. When injected into a vein, the Rexin-G vector is designed to seek out and accumulate in cancerous tumors, therefore, increasing the concentration of the drug in the area of the cancer and not in normal neighbouring organs. When the killer gene gets into the cancer cell, it becomes part of the cell's genes and tells the cancer cell to begin using the new gene instead of the cyclin G1 gene. It is hoped that the Rexin-G will arrest the growth of the cancer or eradicate the tumor.

The goals of the study are to determine how much Rexin-G can be given to a patient, to assess how long Rexin-G stays in the body when injected into a vein, and if the drug would cause antibodies to form, transfer the gene to normal tissues or pass on the gene to another person or the person's offspring. The final goal is to determine if the Rexin-G vector can shrink the tumor by comparing the size of the tumor nodules measured by CT scan or MRI before and after the Rexin-G treatment.
FIELD: chemical industry. SUBSTANCE: described are new benzazepin-, benzoxazepin, benzothiazepin N-acetic acid derivatives of general formula I:   wherein R 1  is (lower) alkoxy (lower) alkyl group, lower alkoxy residue of which group is substituted by lower alkoxy group, phenyl (lower) alkyl group; or phenyloxy (lower) alkyl group which is optionally substituted by lower alkyl, lower alkoxy or halogen in phenyl ring, or naphthyl (lower) alkyl group; A is CH 2 , O or S; R 2  is hydrogen or halogen; R 3  is hydrogen or halogen; R 4  is hydrogen or biolabile ester-forming group; R 5  is hydrogen or biolabile ester - forming group and physiologically tolerable salts of acids of formula I. Said compounds have useful pharmacological properties which are effective with respect to heart and show clearly expressed suppressing effect on neutral endopeptidase, diminish high heart filling pressure that occurs because of heart insufficiency and thus discharge heart and may induce greater liuresis. Also described are method of preparing compounds of formula I and drug that contains said compounds. EFFECT: improved properties of the title compounds. 9 cl, 21 ex, 1 tbl
PROBLEM TO BE SOLVED: To provide powder for hydrogen generation capable of efficiently providing a target with hydrogen for a long term.SOLUTION: If applied to skin and the like as a cosmetic and medicament, an effect exerted by hydrogen would be efficiently provided. The inventors paid attention on the fact that, by virtue of using powder upon application to skin, moisture from skin is efficiently absorbed with powder and that the moisture is retained to accomplish the invention. To solve the problem, the powder for hydrogen generation which contains a substance reacting with water to generate hydrogen is provided. The powder for hydrogen generation of the invention is capable of providing a target, e.g. skin and the like, with hydrogen for a long term and exerting effects, such as prevention of skin aging, reduction of oxidative stress, prevention of adult diseases and anti-aging. Therefore, the invention may be preferably utilized in a broad field such as a cosmetic, quasi drug and medicament.
The invention relates to Hindu lotus petiole qi-rectifying and depression-resolving paste. The Hindu lotus petiole qi-rectifying and depression-resolving paste is prepared from carefully-chosen Chinese herbal medicines according to a reasonable formula and contains effective ingredients such as Hindu lotus petiole, fingered citron, radix bupleuri, citron, dried orange peel and rose. Competition is very fierce in society now and people frequently is in a stress and depression life state so that people easily suffers from emotional diseases such as qi movement disorder, internal organ qi-blood imbalance, affect-mind dissatisfaction, unhealthy four limbs, climacteriumm, vegetative nerve functional disturbance and depression syndrome. Climacterium is a transitional period in which ovarian functions gradually decline from a thriving state to a complete obliteration state and comprises a menopause period and periods before and after menopause. Climacterium of the men is started from 50-60 ages. The vegetative nerve functional disturbance is internal organ function imbalance syndrome. The vegetative nerve functional disturbance comprises circulatory system function, digestive system function or sexual function imbalance, which is psychological and social factor-caused temporary imbalance of a part of human parts and produces neuroendocrine-related change without organizational structure pathologic change. The Hindu lotus petiole qi-rectifying and depression-resolving paste has effects of opening mind and rectifying qi, soothing liver and resolving depression, dredging channels, moving qi and relieving pain. The Hindu lotus petiole qi-rectifying and depression-resolving paste is suitable for affect-mind dissatisfaction diseases such as vegetative nerve functional disturbance, depression and depression syndrome.
NEW MATERIAL:A quinone derivative expressed by formula I (R is lower alkyl or lower alkoxy; A is -CH2-, -CO- or formula II; n is 2-8; R<1> is carboxylic acid acyl). EXAMPLE:2,3,5-Trimethyl-6-(6'-hydroxyhexyl)-1,4-benzoquinone. USE:A medicine, capable of exhibiting remarkably action on lysosomal membranes, immunological promoting and smooth muscle relaxant action and physiological biological resistance control action on animals including humans and particularly useful as an immunological adjuvant. PREPARATION:A compound expressed by formula III as a raw material is reacted with a carboxylic acid or a reactive derivative thereof to afford the aimed compound expressed by formula I. Furthermore, the raw material compound expressed by formula III is synthesized by using a compound expressed by formula IV (X and Y are OH, etc.) or a compound expressed by formula V as a starting substance.
Main study participants will be evaluated at baseline, monitored and followed for a 1 year period with the option to participate in a 1 year extension. Participants in the CSF substudy will be followed for two years and will receive two additional doses of 600 mg ocrelizumab at Weeks 48 and 72.